NEUREN SHARE PURCHASE PLAN RAISES $2 MILLION

Melbourne, Australia, 27 November 2013: Neuren Pharmaceuticals (ASX: NEU) announced today that approximately 17.6 million new shares have been issued under its completed Share Purchase Plan (SPP) after Neuren accepted valid applications totalling approximately $2 million.

The SPP was announced on 22 October 2013 when Neuren successfully completed a placement of new shares to professional and sophisticated investors at 11.5 cents per share, providing additional capital of $21.5 million. The funds from the placement and the SPP will enable Neuren to accelerate execution of its development and commercialisation strategy by:

- Ensuring full funding through to completion of four Phase 2 clinical trials of NNZ-2566 in Fragile X Syndrome, Rett Syndrome, Concussion and Traumatic Brain Injury.
- Optimising the manufacturing process for commercial supply of NNZ-2566.
- Advancing Neuren’s second drug product NNZ-2591 through pre-clinical development.

About Neuren
Neuren Pharmaceuticals Limited (Neuren) is a publicly listed biopharmaceutical company focusing on the development of new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions such as Rett Syndrome and Fragile X Syndrome as well as acute neurological injuries. Neuren presently has a clinical stage molecule, NNZ-2566 in two Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

For more information, please contact:
Dr Richard Treagus, Executive Chairman
rtreagus@neurenpharma.com
Tel: +61 417 520 509

Jon Pilcher, CFO & Company Secretary
jpilcher@neurenpharma.com
Tel: +61 438 422 271